Dynamics of testosterone and prolactin levels, blood pressure and parameters of cardiovascular remodeling in hypertensive men with androgen deficiency in the course of treatment
Keywords:testosterone, prolactin, hypertension, irbesartan, nifedipine
Numerous previous and up-to-date guidelines for antihypertensive treatment do not highlight the problem of interrelations between sexual dysfunction and hypertension itself or with the use of frequently prescribed medications. Changes in testosterone and prolactin concentrations in men undergoing antihypertensive treatment are still not well described.
The aim of the study was to investigate the impact of combined antihypertensive treatment with the addition of phenibut on testosterone and prolactin concentrations, blood pressure and parameters of cardiovascular remodeling in hypertensive men with androgen deficiency.
Materials and methods. A total of 113 men with stage II essential hypertension were recruited to participate in the study. All patients were subjected to routine clinical examination, evaluation of total (TT), free testosterone (FT) and prolactin using ELISA, 24-hour blood pressure monitoring (24-hour BPM), assessment of central aortic pressure and arterial stiffness, transthoracic echocardiography. All study subjects were prescribed the combined antihypertensive treatment with irbesartan and nifedipine. Depending on treatment scheme, all patients were divided into four groups: group 1A consisted of men with low TT who received phenibut in addition to antihypertensive treatment, group 1B – patients with androgen deficiency on antihypertensive treatment only, group 2A – patients with normal TT with the addition of phenibut, group 2B – men with normal TT on antihypertensive medications only.
Results. As a result of prescribed treatment, TT and FT levels increased with discordant changes in the concentration of prolactin: a statistically significant increase in TT (29.72 %, P = 0.0002) and FT (28.08 %, P = 0.0003) with a significant decrease in prolactin concentrations (10.68 %, P = 0.008) were in the group 1A. All patients had positive 24-hour BPM dynamics, parameters of central aortic pressure and cardiovascular remodeling. Patients with androgen deficiency with the addition of phenibut had the highest reduction rates in 24-hour BPM values, central SBP, DBP, PBP, mean BP, augmentation index, RWTT, pulse pressure amplification, CAVIa and were characterized by significant improvement of longitudinal LV deformation and diastolic function.
Conclusions. The use of combined antihypertensive therapy with irbesartan and nifedipine with the addition of phenibut in men with androgen
deficiency contributes to the achievement of target blood pressure levels and improvement of cardiovascular remodeling parameters.
Zhou, B., Bentham, J., Di Cesare, M., Bixby, H., Danaei, G., Hajifathalian, K., et al. (2018). Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. International Journal Of Epidemiology, 47(3), 872–883i. doi: 10.1093/ije/dyy016
Javaroni, V., & Neves, M. (2012). Erectile Dysfunction and Hypertension: Impact on Cardiovascular Risk and Treatment. International Journal Of Hypertension, 2012, 627278. doi: 10.1155/2012/627278
Manolis, A., & Doumas, M. (2008). Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. Journal Of Hypertension, 26(11), 2074–2084. doi: 10.1097/hjh.0b013e32830dd0c6.
Al Khaja, K., Sequeira, R. P., Alkhaja, A. K., & Damanhori, A. H. (2016). Antihypertensive Drugs and Male Sexual Dysfunction. Journal Of Cardiovascular Pharmacology And Therapeutics, 21(3), 233-244. doi: 10.1177/1074248415598321
Nicolai, M., Liem, S., Both, S., Pelger, R., Putter, H., Schalij, M., & Elzevier, H. (2013). A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. Netherlands Heart Journal, 22(1), 11–19. doi: 10.1007/s12471-013-0482-z
Yang, L., Yu, J., Ma, R., Zhao, F., Lin, X., Liu, P. et al. (2013). The Effect of Combined Antihypertensive Treatment (Felodipine with Either Irbesartan or Metoprolol) on Erectile Function: A Randomized Controlled Trial. Cardiology, 125(4), 235–241. doi: 10.1159/000350955
Ogihara, T., & Kuuramoto, K. (2000). Effect of Long-Term Treatment with Antihypertensive Drugs on Quality of Life of Elderly Patients with Hypertension: A Double-Blind Comparative Study between a Calcium Antagonist and a Diuretic. Hypertension Research, 23(1), 33–37. doi: 10.1291/hypres.23.33
Lin, L., Wang, D., Wang, W., Cheng, Y., Su, D., & Liu, A. (2015). Long-Term Treatment of Clonidine, Atenolol, Amlodipine and Dihydrochlorothiazide, but Not Enalapril, Impairs the Sexual Function in Male Spontaneously Hypertensive Rats. PLOS ONE, 10(1), e0116155. doi: 10.1371/journal.pone.0116155
Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. (2013). European Heart Journal, 34(28), 2159–2219. doi: 10.1093/eurheartj/eht151
Ma, R., Yu, J., Xu, D., Yang, L., Lin, X., Zhao, F., & Bai, F. (2012). Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. Journal Of Hypertension, 30(1), 210–216. doi: 10.1097/hjh.0b013e32834e1e2e
Bobrie, G. (2012). I-ADD Study: Assessment of Efficacy and Safety Profile of Irbesartan/Amlodipine Fixed-Dose Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled With Irbesartan 150 mg Monotherapy: A Multicenter, Phase III, Prospective, Randomized, Open-Label With Blinded–End Point Evaluation Study. Clinical Therapeutics, 34(8), 1720–1734.e3. doi: 10.1016/j.clinthera.2012.07.001
Bobrie, G. (2012). I-COMBINE Study: Assessment of Efficacy and Safety Profile of Irbesartan/Amlodipine Fixed-Dose Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled With Amlodipine 5 mg Monotherapy: A Multicenter, Phase III, Prospective, Randomized, Open-Label With Blinded–End Point Evaluation Study. Clinical Therapeutics, 34(8), 1705–1719. doi: 10.1016/j.clinthera.2012.06.026
Kobalava, Zh. D. (2014). Fiksirovannaya kombinaciya irbesartan/amlodipin: e'ffektivnost' i bezopasnost' primeneniya 4 dozovykh rezhimov u pacientov s arterial'noj gipertoniej [Fixed Irbesartan/Amlodipine Combination: Efficacy and Safety of the Use of Four Dosing Regimens in Patients With Arterial Hypertension]. Kardiologiya, 54(6), 15–20. [in Russian].
Ishimitsu, T., Ohno, E., Nakano, N., Furukata, S., Akashiba, A., Minami, J., et al. (2011). Combination of Angiotensin II Receptor Antagonist with Calcium Channel Blocker or Diuretic as Antihypertensive Therapy for Patients with Chronic Kidney Disease. Clinical And Experimental Hypertension, 33(6), 366–372. doi: 10.3109/10641963.2010.503299
Yagi, S., Takashima, A., Mitsugi, M., Wada, T., Hotchi, J., Aihara, K., et al. (2015). Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension. Therapeutics And Clinical Risk Management, 11, 83–8. doi: 10.2147/tcrm.s72299
Gaudio, C., Ferri, F., Giovannini, M., Pannarale, G., Puddu, P., Vittore, A., et al. (2003). Comparative Effects of Irbesartan Versus Amlodipine on Left Ventricular Mass Index in Hypertensive Patients with Left Ventricular Hypertrophy. Journal Of Cardiovascular Pharmacology, 42(5), 622–628. doi: 10.1097/00005344-200311000-00007
Malmqvist, K., Kahan, T., Edner, M., Held, C., Hägg, A., Lind, L., et al. (2001). Regression of left ventricular hypertrophy in human hypertension with irbesartan. Journal Of Hypertension, 19(6), 1167–1176. doi: 10.1097/00004872-200106000-00023
Mörtsell, D., Malmqvist, K., Held, C., & Kahan, T. (2007). Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. Journal Of Internal Medicine, 261(5), 472–479. doi: 10.1111/j.1365-2796.2007.01775.x
Kolesnik, M. Y. (2015). Deformatsіia mіokarda lіvoho shlunochka pry arterіalnіi hіpertenzіi [The Left Ventricle Myocardial Deformation In Arterial Hypertension]. Svit medytsyny ta biolohii, 1(48), 35–39. [in Ukrainian].
Toh, N., Ishii, K., Kihara, H., Iwakura, K., Watanabe, H., Yoshikawa, J., & Ito, H. (2016). Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients. Circulation Journal, 80(2), 426–434. doi: 10.1253/circj.cj-15-0815
Müller-Brunotte, R., Kahan, T., Malmqvist, K., Ring, M., & Edner, M. (2006). Tissue Velocity Echocardiography Shows Early Improvement in Diastolic Function With Irbesartan and Atenolol Therapy in Patients With Hypertensive Left Ventricular HypertrophyResults From the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). American Journal Of Hypertension, 19(9), 927–936. doi: 10.1016/j.amjhyper.2006.02.009
How to Cite
LicenseAuthors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)